Genkyotex, a pharma company based in Geneva, is the leading developer of NOX inhibitors. The Company is developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. Genkyotex has built a pipeline of NOX inhibitors for different diseases led by the NOX1&4 inhibitor GKT137831, which is in advanced clinical development in several blockbuster indications.

Menu